Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which steroid works better for chronic cough? a Head-to-Head trial aims to find out

NCT ID NCT07777796

Disease control Sponsor: Silesian University of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 25, 2026 · Updated 3 times

Summary

This trial compares two common steroid treatments for chronic cough that occurs with nose or sinus symptoms, known as upper airway cough syndrome. Adults with chronic cough and signs of rhinitis or sinusitis are randomly assigned to either an inhaled steroid (budesonide) or a steroid nasal spray (mometasone furoate) for 4 weeks. If the cough hasn't resolved, treatment is adjusted for another 4 weeks. The main question is whether the inhaled steroid reduces cough severity more than the nasal spray after 4 weeks, with secondary measures of quality of life and response to adjusted treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Inhaled budesonide (a corticosteroid) compared with intranasal mometasone furoate (a corticosteroid nasal spray)
What this could lead to
If inhaled steroids work better, doctors may have clearer guidance on choosing between inhaler and nasal spray for chronic cough with upper airway symptoms.
What could go wrong
This is a small, single-center trial, and results may not apply broadly. Both treatments are already approved, so the benefit is mainly in guiding treatment choice, not a breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

57 people

The number who actually took part.

Started

Jul 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with chronic cough and signs of chronic upper airway disease Exclusion Criteria: * Symptoms of an acute respiratory tract infection within 4 weeks prior to enrolment. * Diagnosis of any active chronic respiratory disease. * Diagnosis of other cause of chronic cough. * Use of corticosteroids (oral, intranasal, inhaled, intravenous) within 3 months prior to enrolment. * Chronic use of angiotensin-converting enzyme (ACE) inhibitors within 1 month prior to enrolment. * Smoking of tobacco products within 6 months prior to enrolment * Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic cough (CC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Cough chronic rhinitis upper airway cough syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic cough (CC) Chronic rhinitis Upper airway cough syndrome

Contacts and locations

Locations

  • Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia

    Katowice, Silesian Voivodeship, 40-635, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.